PubMed چکیده/رکورد

Quantitative evaluation of pyuria with a hemocytometer in children on clean intermittent catheterization.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

INTRODUCTION: Urinalysis is commonly used to diagnose urinary tract infections (UTIs), but its accuracy is reduced in children undergoing clean intermittent catheterization (CIC) because of asymptomatic pyuria. This study aimed to determine the optimal urinary leukocyte cutoff value for diagnosing UTIs using a hemocytometer. METHODS: This retrospective observational study included children (<16 years) on CIC at a tertiary children's hospital between April 2020 and March 2025. Quantitative urinalysis was performed using a UF-1500 hemocytometer. UTI was defined as bacteriuria ≥104 CFU/mL accompanied by antimicrobial treatment. Receiver operating characteristic (ROC) curve analysis was used to identify the optimal cutoff for urinary white blood cell (WBC) count. RESULTS: Among 134 patients (2871 specimens), 101 specimens were classified as infection cases (3.5%). Median urinary WBC counts were markedly higher during infection (1514.6/mm3) than during non-infectious periods (21.2/mm3; p < 0.001). ROC analysis yielded an area under the curve of 0.950 (95% CI, 0.935-0.964). The optimal cutoff value was 220.8/mm3, corresponding to 94.1% sensitivity, 84.7% specificity, and 99.7% negative predictive value. WBC counts did not significantly differ among infections caused by different uropathogens. CONCLUSIONS: Hemocytometer-based quantification of pyuria provided high diagnostic accuracy and may be particularly useful as a rule-out test for UTIs in children undergoing CIC.

متن کامل اصلی

متن در JumpToDate ذخیره نشده است.

برای بررسی دسترسی کتابخانه‌ای یا خرید، رکورد اصلی را باز کنید.

رفتن به منبع اصلی

کلیدواژه‌ها

ChildrenClean intermittent catheterizationHemocytometerPyuriaUrinary tract infection
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

Pharmacological strategies for slowing the rise of creatinine and urea nitrogen in diabetic kidney disease: A scoping review.

BACKGROUND: Adolescent diabetic kidney disease (DKD) represents an early-onset microvascular complication characterized by prolonged metabolic exposure and accelerated renal decline. Elevated serum creatinine and blood urea nitrogen (BUN) are key biochemical indicators of impaired renal function. OBJECTIVES: This scoping review aims to systematically map and evaluate pharmacological strategies for slowing the rise of creatinine and BUN…

PubMed2026

Dried Blood Spots for Doping Purpose-Two-Step Protocol for Analysis of Non-Threshold Substances and Anabolic Steroid Esters From One Spot/Pebble.

Analytical performance in anti-doping science continues to evolve through the identification of novel metabolites, improved detection sensitivity, and the use of alternative biological matrices. In recent years, dried blood spots (DBS) have gained increasing attention in doping control due to advantages such as improved analyte stability and simplified, cost-effective sample collection, shipment, and storage. However, DBS sampling is i…

PubMed2026

Hematology and Serum Biochemistry Reference Intervals for Captive-Born Owl Monkeys (Aotus nancymae): Effects of Age and Sex.

BACKGROUND: Owl monkeys (Aotus spp.) are a nocturnal nonhuman primate (NHP) native to central and South America that are used as infectious disease research models for human diseases, such as malaria and human immunodeficiency virus. Natural and infectious diseases may cause alterations in the hematology and serum biochemistry values, which necessitate the availability of reliable reference intervals for healthy animals. METHODS: In th…

PubMed2026

Quantitation of Tucatinib, a Novel Tyrosine Kinase Inhibitor in Dried Blood Spot (DBS) With LC-ESI-MS/MS: Application to a Pharmacokinetic Study in Mice.

Tucatinib (Irbinitinib, ARRY-380), a potent oral, selective HER2 kinase inhibitor that the FDA, has approved for the treatment of HER2-positive metastatic breast cancer and colorectal cancer. Tucatinib provides a powerful, targeted therapy for HER2-positive cancers, showing substantial benefits in survival and disease control, especially for patients with difficult-to-treat brain metastases, extending options beyond standard chemothera…